ExodusPoint Capital Management LP Has $1.81 Million Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

ExodusPoint Capital Management LP lessened its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 6.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 63,239 shares of the specialty pharmaceutical company’s stock after selling 4,213 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Collegium Pharmaceutical were worth $1,812,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COLL. FMR LLC grew its holdings in shares of Collegium Pharmaceutical by 1,532.2% during the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock valued at $1,459,000 after buying an additional 35,439 shares in the last quarter. Verition Fund Management LLC grew its stake in Collegium Pharmaceutical by 35.1% during the 3rd quarter. Verition Fund Management LLC now owns 14,042 shares of the specialty pharmaceutical company’s stock valued at $543,000 after acquiring an additional 3,652 shares in the last quarter. Janus Henderson Group PLC grew its stake in Collegium Pharmaceutical by 399.4% during the 3rd quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company’s stock valued at $2,686,000 after acquiring an additional 55,572 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Collegium Pharmaceutical by 17.2% in the 3rd quarter. Wellington Management Group LLP now owns 114,640 shares of the specialty pharmaceutical company’s stock valued at $4,430,000 after purchasing an additional 16,784 shares during the period. Finally, Barclays PLC lifted its position in shares of Collegium Pharmaceutical by 152.2% in the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after purchasing an additional 45,291 shares in the last quarter.

Insider Buying and Selling

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 10,445 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total value of $313,454.45. Following the sale, the chief financial officer now owns 165,246 shares of the company’s stock, valued at $4,959,032.46. This trade represents a 5.95 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 109,193 shares of company stock valued at $3,243,594. Company insiders own 3.98% of the company’s stock.

Wall Street Analysts Forecast Growth

COLL has been the subject of several recent research reports. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Piper Sandler dropped their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $25.41 on Wednesday. The stock has a market capitalization of $816.47 million, a P/E ratio of 10.95 and a beta of 0.76. The business has a 50-day moving average of $29.60 and a two-hundred day moving average of $31.89. Collegium Pharmaceutical, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The firm had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. On average, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.